ALEMBIC PHARMACEUTICALS
|
ALEMBIC PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr |
Equity - Authorised | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹40 Cr |
Equity - Issued | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr |
Equity Paid Up | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 |
Share Warrants & Outstandings | - | - | - | - | - |
Total Reserves | ₹5,152 Cr | ₹4,779 Cr | ₹4,331 Cr | ₹5,198 Cr | ₹5,028 Cr |
Securities Premium | ₹748 Cr | ₹748 Cr | ₹748 Cr | ₹748 Cr | ₹748 Cr |
Capital Reserves | - | - | - | - | - |
Profit & Loss Account Balance | ₹4,394 Cr | ₹4,027 Cr | ₹3,568 Cr | ₹2,554 Cr | ₹2,385 Cr |
General Reserves | ₹0.24 Cr | ₹0.24 Cr | ₹0.24 Cr | ₹1,845 Cr | ₹1,770 Cr |
Other Reserves | ₹8.79 Cr | ₹3.25 Cr | ₹14 Cr | ₹51 Cr | ₹124 Cr |
Reserve excluding Revaluation Reserve | ₹5,152 Cr | ₹4,779 Cr | ₹4,331 Cr | ₹5,198 Cr | ₹5,028 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹5,191 Cr | ₹4,818 Cr | ₹4,370 Cr | ₹5,238 Cr | ₹5,067 Cr |
Minority Interest | ₹-1.42 Cr | - | - | - | - |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | - | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | - | - | - | - | ₹200 Cr |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | ₹200 Cr |
Deferred Tax Assets / Liabilities | ₹-166 Cr | ₹-170 Cr | ₹-123 Cr | ₹-5.89 Cr | ₹4.21 Cr |
Deferred Tax Assets | ₹306 Cr | ₹301 Cr | ₹206 Cr | ₹204 Cr | ₹185 Cr |
Deferred Tax Liability | ₹140 Cr | ₹131 Cr | ₹83 Cr | ₹198 Cr | ₹189 Cr |
Other Long Term Liabilities | ₹47 Cr | ₹63 Cr | ₹69 Cr | ₹72 Cr | ₹72 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹124 Cr | ₹110 Cr | ₹106 Cr | ₹96 Cr | ₹86 Cr |
Total Non-Current Liabilities | ₹5.05 Cr | ₹2.75 Cr | ₹52 Cr | ₹162 Cr | ₹361 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹880 Cr | ₹736 Cr | ₹680 Cr | ₹706 Cr | ₹669 Cr |
Sundry Creditors | ₹880 Cr | ₹736 Cr | ₹680 Cr | ₹706 Cr | ₹669 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹232 Cr | ₹224 Cr | ₹251 Cr | ₹517 Cr | ₹558 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹17 Cr | ₹16 Cr | ₹40 Cr | ₹69 Cr | ₹24 Cr |
Interest Accrued But Not Due | ₹1.35 Cr | ₹0.88 Cr | ₹0.27 Cr | ₹5.38 Cr | ₹10 Cr |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | ₹200 Cr | ₹300 Cr |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹213 Cr | ₹207 Cr | ₹211 Cr | ₹242 Cr | ₹224 Cr |
Short Term Borrowings | ₹1,196 Cr | ₹430 Cr | ₹636 Cr | ₹430 Cr | ₹0.02 Cr |
Secured ST Loans repayable on Demands | ₹118 Cr | ₹100 Cr | ₹165 Cr | - | ₹0.02 Cr |
Working Capital Loans- Sec | ₹118 Cr | ₹100 Cr | ₹165 Cr | - | ₹0.02 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹960 Cr | ₹230 Cr | ₹306 Cr | ₹430 Cr | ₹-0.02 Cr |
Short Term Provisions | ₹207 Cr | ₹131 Cr | ₹74 Cr | ₹178 Cr | ₹307 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹121 Cr | ₹65 Cr | ₹3.87 Cr | ₹114 Cr | ₹255 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹86 Cr | ₹65 Cr | ₹70 Cr | ₹64 Cr | ₹52 Cr |
Total Current Liabilities | ₹2,514 Cr | ₹1,520 Cr | ₹1,641 Cr | ₹1,831 Cr | ₹1,533 Cr |
Total Liabilities | ₹7,709 Cr | ₹6,341 Cr | ₹6,064 Cr | ₹7,230 Cr | ₹6,961 Cr |
ASSETS | |||||
Gross Block | ₹4,117 Cr | ₹3,875 Cr | ₹3,468 Cr | ₹2,840 Cr | ₹2,545 Cr |
Less: Accumulated Depreciation | ₹1,594 Cr | ₹1,329 Cr | ₹1,069 Cr | ₹1,042 Cr | ₹757 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹2,524 Cr | ₹2,547 Cr | ₹2,398 Cr | ₹1,798 Cr | ₹1,788 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹837 Cr | ₹524 Cr | ₹601 Cr | ₹2,206 Cr | ₹1,944 Cr |
Non Current Investments | ₹127 Cr | ₹93 Cr | ₹96 Cr | ₹118 Cr | ₹49 Cr |
Long Term Investment | ₹127 Cr | ₹93 Cr | ₹96 Cr | ₹118 Cr | ₹49 Cr |
Quoted | - | - | - | - | - |
Unquoted | ₹164 Cr | ₹130 Cr | ₹133 Cr | ₹155 Cr | ₹49 Cr |
Long Term Loans & Advances | ₹31 Cr | ₹33 Cr | ₹54 Cr | ₹35 Cr | ₹37 Cr |
Other Non Current Assets | - | - | - | - | - |
Total Non-Current Assets | ₹3,519 Cr | ₹3,197 Cr | ₹3,150 Cr | ₹4,255 Cr | ₹4,057 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | - | - | - | - | ₹187 Cr |
Quoted | - | - | - | - | - |
Unquoted | - | - | - | - | ₹187 Cr |
Inventories | ₹2,288 Cr | ₹1,644 Cr | ₹1,475 Cr | ₹1,610 Cr | ₹1,486 Cr |
Raw Materials | ₹628 Cr | ₹386 Cr | ₹390 Cr | ₹456 Cr | ₹384 Cr |
Work-in Progress | ₹125 Cr | ₹70 Cr | ₹75 Cr | ₹89 Cr | ₹67 Cr |
Finished Goods | ₹1,113 Cr | ₹886 Cr | ₹796 Cr | ₹852 Cr | ₹884 Cr |
Packing Materials | ₹199 Cr | ₹94 Cr | ₹69 Cr | ₹61 Cr | ₹59 Cr |
Stores  and Spare | ₹49 Cr | ₹42 Cr | ₹38 Cr | ₹36 Cr | ₹29 Cr |
Other Inventory | ₹174 Cr | ₹166 Cr | ₹108 Cr | ₹117 Cr | ₹64 Cr |
Sundry Debtors | ₹1,400 Cr | ₹1,025 Cr | ₹1,046 Cr | ₹807 Cr | ₹349 Cr |
Debtors more than Six months | ₹16 Cr | ₹27 Cr | ₹23 Cr | ₹22 Cr | ₹98 Cr |
Debtors Others | ₹1,419 Cr | ₹1,033 Cr | ₹1,052 Cr | ₹819 Cr | ₹275 Cr |
Cash and Bank | ₹90 Cr | ₹127 Cr | ₹82 Cr | ₹69 Cr | ₹106 Cr |
Cash in hand | ₹0.46 Cr | ₹1.04 Cr | ₹0.28 Cr | ₹0.38 Cr | ₹0.26 Cr |
Balances at Bank | ₹90 Cr | ₹126 Cr | ₹82 Cr | ₹69 Cr | ₹106 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹69 Cr | ₹60 Cr | ₹55 Cr | ₹52 Cr | ₹79 Cr |
Interest accrued on Investments | - | - | - | - | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹69 Cr | ₹50 Cr | ₹55 Cr | ₹37 Cr | ₹36 Cr |
Other current_assets | - | ₹9.81 Cr | - | ₹15 Cr | ₹43 Cr |
Short Term Loans and Advances | ₹343 Cr | ₹289 Cr | ₹255 Cr | ₹437 Cr | ₹698 Cr |
Advances recoverable in cash or in kind | ₹50 Cr | ₹65 Cr | ₹58 Cr | ₹56 Cr | ₹69 Cr |
Advance income tax and TDS | ₹113 Cr | ₹106 Cr | ₹87 Cr | ₹139 Cr | ₹269 Cr |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹179 Cr | ₹118 Cr | ₹110 Cr | ₹241 Cr | ₹360 Cr |
Total Current Assets | ₹4,190 Cr | ₹3,144 Cr | ₹2,914 Cr | ₹2,975 Cr | ₹2,904 Cr |
Net Current Assets (Including Current Investments) | ₹1,675 Cr | ₹1,624 Cr | ₹1,273 Cr | ₹1,144 Cr | ₹1,371 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹7,709 Cr | ₹6,341 Cr | ₹6,064 Cr | ₹7,230 Cr | ₹6,961 Cr |
Contingent Liabilities | ₹69 Cr | ₹55 Cr | ₹109 Cr | ₹63 Cr | ₹100 Cr |
Total Debt | ₹1,196 Cr | ₹430 Cr | ₹636 Cr | ₹630 Cr | ₹500 Cr |
Book Value | - | 245.14 | 222.36 | 266.47 | 257.80 |
Adjusted Book Value | 264.10 | 245.14 | 222.36 | 266.47 | 257.80 |
Compare Balance Sheet of peers of ALEMBIC PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
ALEMBIC PHARMACEUTICALS | ₹19,947.0 Cr | 4.4% | 2% | 18.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹400,017.0 Cr | -0.2% | -0.5% | 10.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹181,867.0 Cr | 4% | 4.8% | 50.5% | Stock Analytics | |
CIPLA | ₹122,451.0 Cr | 0.4% | 3.1% | 1.6% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹115,620.0 Cr | 5.9% | 9.1% | 23% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹106,572.0 Cr | -4.8% | 2.2% | 2.9% | Stock Analytics |
ALEMBIC PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ALEMBIC PHARMACEUTICALS | 4.4% |
2% |
18.5% |
SENSEX | 2% |
2.8% |
6.4% |
You may also like the below Video Courses